Shots:
- Chugai will receive an upfront, development milestone and royalties if the compound is launch as an approved Ab drug. Additionally, Chugai will receive a fee for technology access
- Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of therapeutic Abs
- Novo Nordisk will utilize Chugai’s Ab engineering technologies targeting the unmet medical needs and create novel medicines
Click here to read full press release/ article | Ref: Chugai | Image: Peter Boyle Solicitors
The post Novo Nordisk Signs a License Agreement with Chugai for Antibody Engineering Technologies first appeared on PharmaShots.
